Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab vs Aflibercept in Macular Edema Secondary to CRVO/HRVO
jRCT2031200454Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of faricimab in central retinal vein occlusion with macular edema and macular edema (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline in best-corrected visual acuity (BCVA) at Week 24. Started Jun 2021; status: completed.
02
Drugs
faricimab
03
Conditions
central retinal vein occlusion with macular edemamacular edema
Beyond the preview
Go deeper on jRCT2031200454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200454.